Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERKULES-2: ERAS-007 or ERAS-601 in Advanced NSCLC
NCT04959981Phase 1Completed
- Sponsor
- Erasca
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-007 and ERAS-601 in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Erasca. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 2 more. Started Sep 2021; status: completed.
02
Drugs
ERAS-007ERAS-601
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04959981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959981.